



**World Health
Organization**

INN Working Document 13.332

09/07/2013

Addendum¹ to
***"The use of stems in the selection of International
Nonproprietary names (INN) for pharmaceutical
substances"*** WHO/EMP/QSM/2011.3

Programme on International Nonproprietary Names (INN)

Quality Assurance and Safety: Medicines (QSM)

World Health Organization, Geneva

© World Health Organization 2013 - All rights reserved. The contents of this document may not be reviewed, abstracted, quoted, referenced, reproduced, transmitted, distributed, translated or adapted, in part or in whole, in any form or by any means, without explicit prior authorization of the WHO INN Programme.

This document contains the collective views of the INN Expert Group and does not necessarily represent the decisions or the stated policy of the World Health Organization.

Addendum¹ to "The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances" - WHO/EMP/QSM/2011.3

¹ This addendum is a cumulative list of all new stems selected by the INN Expert Group since the publication of *"The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances"* 2011.

In bold: newly selected stem

-lisib	phosphatidylinositol 3-kinase inhibitors, antineoplastics
---------------	--

acalisib (109), apitolisib (108), buparlisib (106), copanlisib (108), dactolisib (107), idelalisib (107), panulisib (109), pictilisib (107), pilaralisib (108), recilisib (108)

-lutamide	non-steroid antiandrogens
------------------	----------------------------------

bicalutamide (70), enzalutamide (107), flutamide (33), nilutamide (56), topilutamide (91)

(b) aceglutamide (15)

-rixin	chemokine CXCR receptors antagonists
---------------	---

dazirixin (107), elubrixin (107), ladarixin (105), navarixin (105), reparixin (91)

-tibant	bradykinin receptor antagonists
----------------	--

anatibant (88), deltibant (75), fasitibant chloride (103), icatibant (67), safotibant (105)

vir antivirals (undefined group)

-buvir RNA polymerase (NS5B) inhibitors

filibuvir (101), lomibuvir (107), nesbuvir (98), setrobuvir (106),
tegobuvir (103)

-zomib proteasome inhibitors

bortezomib (88), carfilzomib (97), delanzomib (105), ixazomib (104),
marizomib (102)

Update of the Annex 4
(new infixes are underlined)

INNs FOR GENE THERAPY PRODUCTS

The following nomenclature scheme was adopted by the members of the INN Expert Group designated to deal with the selection of nonproprietary names in December 2005 after a broad consultative process.

A two-word name approach has been selected:

Word 1	-gene	<i>gene component</i>
	<u>-cima-</u>	<u>cytosine deaminase</u>
	-ermin-	growth factor
	-kin-	interleukin
	-lim-	immunomodulator
	<u>-lip-</u>	<u>human lipoprotein lipase</u>
	-mul-	multiple gene
	<u>-stim-</u>	<u>colony stimulating factor</u>
	<u>-tima-</u>	<u>thymidine kinase</u>
	-tusu-	tumour suppression

prefix	infix		suffix
random to contribute to euphonious and distinctive name	<u>-cima-</u> -ermin- -kin- -lim- <u>-lip-</u> -mul- <u>-stim-</u> <u>-tima-</u> -tusu- etc.	<u>cytosine deaminase</u> growth factors interleukins immunomodulators <u>human lipoprotein lipase</u> multiple genes <u>colony stimulating factor</u> <u>thymidine kinase</u> tumour suppression	-(a vowel)gene e.g. -(o)gene

Word 2	-vec -repvec	<i>vector component is a virus replicating viral vector</i>
---------------	-----------------	---

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_28134

